Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
A6NFK2
UPID:
GRCR2_HUMAN
Alternative names:
GRXCR1-like protein; Glutaredoxin domain-containing cysteine-rich protein 1-like protein
Alternative UPACC:
A6NFK2
Background:
Glutaredoxin domain-containing cysteine-rich protein 2, also known as GRXCR1-like protein, plays a crucial role in maintaining cochlear stereocilia bundles essential for sound detection. This protein's involvement in the auditory system underscores its importance in hearing processes.
Therapeutic significance:
Linked to Deafness, autosomal recessive, 101, a condition characterized by moderate to severe bilateral hearing loss without affecting vestibular function, this protein's study could lead to groundbreaking treatments for hearing impairments.